A citation-based method for searching scientific literature

Yves Pommier, Mark J O'Connor, Johann de Bono. Sci Transl Med 2016
Times Cited: 290



Helen E Bryant, Niklas Schultz, Huw D Thomas, Kayan M Parker, Dan Flower, Elena Lopez, Suzanne Kyle, Mark Meuth, Nicola J Curtin, Thomas Helleday. Nature 2005
Times Cited: 2970




List of shared articles



Times cited

PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA.
Emily N Risdon, Cindy H Chau, Douglas K Price, Oliver Sartor, William D Figg. Oncologist 2021
8

BRCA1 and BRCA2 associated breast cancer and the roles of current modelling systems in drug discovery.
Oliver Trusler, Jacob Goodwin, Andrew L Laslett. Biochim Biophys Acta Rev Cancer 2021
0

Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.
Dae-Seok Kim, Cristel V Camacho, W Lee Kraus. Exp Mol Med 2021
11

Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer.
M Chiappa, F Guffanti, F Bertoni, I Colombo, G Damia. Drug Resist Updat 2021
4


Rapid Detection and Signaling of DNA Damage by PARP-1.
Nootan Pandey, Ben E Black. Trends Biochem Sci 2021
3

Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand.
Parasvi S Patel, Arash Algouneh, Razq Hakem. Oncogene 2021
7

Shaping the BRCAness mutational landscape by alternative double-strand break repair, replication stress and mitotic aberrancies.
Colin Stok, Yannick P Kok, Nathalie van den Tempel, Marcel A T M van Vugt. Nucleic Acids Res 2021
1

Modeling DNA trapping of anticancer therapeutic targets using missense mutations identifies dominant synthetic lethal interactions.
Akil Hamza, Leanne Amitzi, Lina Ma, Maureen R M Driessen, Nigel J O'Neil, Philip Hieter. Proc Natl Acad Sci U S A 2021
2

Targeting the nucleotide salvage factor DNPH1 sensitizes BRCA-deficient cells to PARP inhibitors.
Kasper Fugger, Ilirjana Bajrami, Mariana Silva Dos Santos, Sarah Jane Young, Simone Kunzelmann, Geoff Kelly, Graeme Hewitt, Harshil Patel, Robert Goldstone, Thomas Carell,[...]. Science 2021
9

PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data.
Myrto Moutafi, Panagiota Economopoulou, David Rimm, Amanda Psyrri. Oral Oncol 2021
3


Studying PAR-Dependent Chromatin Remodeling to Tackle PARPi Resistance.
Christina Andronikou, Sven Rottenberg. Trends Mol Med 2021
2


Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises.
Melissa M Pham, Natalie Y L Ngoi, Guang Peng, David S P Tan, Timothy A Yap. Trends Cancer 2021
0

Genome-wide CRISPR screens reveal cyclin C as synthetic survival target of BRCA2.
Mengfan Tang, Guangsheng Pei, Dan Su, Chao Wang, Xu Feng, Mrinal Srivastava, Zhen Chen, Zhongming Zhao, Junjie Chen. Nucleic Acids Res 2021
0

Serine-linked PARP1 auto-modification controls PARP inhibitor response.
Evgeniia Prokhorova, Florian Zobel, Rebecca Smith, Siham Zentout, Ian Gibbs-Seymour, Kira Schützenhofer, Alessandra Peters, Joséphine Groslambert, Valentina Zorzini, Thomas Agnew,[...]. Nat Commun 2021
5

Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency.
Ke Cong, Min Peng, Arne Nedergaard Kousholt, Wei Ting C Lee, Silviana Lee, Sumeet Nayak, John Krais, Pamela S VanderVere-Carozza, Katherine S Pawelczak, Jennifer Calvo,[...]. Mol Cell 2021
7


Understanding and overcoming resistance to PARP inhibitors in cancer therapy.
Mariana Paes Dias, Sarah C Moser, Shridar Ganesan, Jos Jonkers. Nat Rev Clin Oncol 2021
5


Replication-dependent cytotoxicity and Spartan-mediated repair of trapped PARP1-DNA complexes.
Liton Kumar Saha, Yasuhisa Murai, Sourav Saha, Ukhyun Jo, Masataka Tsuda, Shunichi Takeda, Yves Pommier. Nucleic Acids Res 2021
0

Tackling PARP inhibitor resistance.
Kasper Fugger, Graeme Hewitt, Stephen C West, Simon J Boulton. Trends Cancer 2021
0

Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1-DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs.
Jeffrey W Johannes, Amber Balazs, Derek Barratt, Michal Bista, Matthew D Chuba, Sabina Cosulich, Susan E Critchlow, Sébastien L Degorce, Paolo Di Fruscia, Scott D Edmondson,[...]. J Med Chem 2021
0

Precision Oncology with Drugs Targeting the Replication Stress, ATR, and Schlafen 11.
Ukhyun Jo, Yasuhisa Murai, Naoko Takebe, Anish Thomas, Yves Pommier. Cancers (Basel) 2021
0

Determinants of Homologous Recombination Deficiency in Pancreatic Cancer.
Max M Wattenberg, Kim A Reiss. Cancers (Basel) 2021
0

CRISPR screens guide the way for PARP and ATR inhibitor biomarker discovery.
Emily M Schleicher, George-Lucian Moldovan. FEBS J 2021
0

DoE Optimization Empowers the Automated Preparation of Enantiomerically Pure [18F]Talazoparib and its In Vivo Evaluation as a PARP Radiotracer.
Gregory D Bowden, Sophie Stotz, Johannes Kinzler, Christian Geibel, Michael Lämmerhofer, Bernd J Pichler, Andreas Maurer. J Med Chem 2021
0


PARP Inhibitors and Haematological Malignancies-Friend or Foe?
Kathryn A Skelding, Lisa F Lincz. Cancers (Basel) 2021
0

WRN helicase safeguards deprotected replication forks in BRCA2-mutated cancer cells.
Arindam Datta, Kajal Biswas, Joshua A Sommers, Haley Thompson, Sanket Awate, Claudia M Nicolae, Tanay Thakar, George-Lucian Moldovan, Robert H Shoemaker, Shyam K Sharan,[...]. Nat Commun 2021
0

Efficacy and Safety of PARP Inhibitors in Advanced or Metastatic Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis.
Xu Liu, Kan Wu, Dan Zheng, Chuanxu Luo, Yu Fan, Xiaorong Zhong, Hong Zheng. Front Oncol 2021
0

Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach.
Stergios Boussios, Peeter Karihtala, Michele Moschetta, Charlotte Abson, Afroditi Karathanasi, Nikolaos Zakynthinakis-Kyriakou, Jake Edward Ryan, Matin Sheriff, Elie Rassy, Nicholas Pavlidis. Invest New Drugs 2020
35

Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer.
Gu Xiao, Devon Lundine, George K Annor, Jorge Canar, Viola Ellison, Alla Polotskaia, Patrick L Donabedian, Thomas Reiner, Galina F Khramtsova, Olufunmilayo I Olopade,[...]. Cancer Res 2020
10

Discovery of Novel Dual Poly(ADP-ribose)polymerase and Phosphoinositide 3-Kinase Inhibitors as a Promising Strategy for Cancer Therapy.
Junwei Wang, Hui Li, Guangchao He, Zhaoxing Chu, Kewen Peng, Yiran Ge, Qihua Zhu, Yungen Xu. J Med Chem 2020
10

53BP1: a DSB escort.
Zachary Mirman, Titia de Lange. Genes Dev 2020
56


Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer.
Feiyue Zheng, Yi Zhang, Shuang Chen, Xiang Weng, Yuefeng Rao, Hongmei Fang. Biomed Pharmacother 2020
18

Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression.
Daniel Rathkey, Manakamana Khanal, Junko Murai, Jingli Zhang, Manjistha Sengupta, Qun Jiang, Betsy Morrow, Christine N Evans, Raj Chari, Patricia Fetsch,[...]. J Thorac Oncol 2020
21

Mutations of BRCA2 in canine mammary tumors and their targeting potential in clinical therapy.
Pauline Thumser-Henner, Katarzyna J Nytko, Carla Rohrer Bley. BMC Vet Res 2020
7